Our News on Newswise

La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research

Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology (LJI), a globally recognized non-profit research organization dedicated to understanding the power of the immune...
1-Aug-2022 6:00 AM EDT Add to Favorites

Newswise: 62db157445d44_KronenbergHVEM.png

The Gut Patrol

Cells in the gut send secret messages to the immune system. Thanks to new research from La Jolla Institute for Immunology (LJI) scientists, we can finally get a look at what they're saying.
24-Jul-2022 8:30 PM EDT Add to Favorites

Newswise: 62d9c1289c71e_graphicalabstract.png

Your Body Remembers Common Cold Coronaviruses From Childhood How Can You Get the Same Immunity to Covid-19?

For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).
21-Jul-2022 5:25 PM EDT Add to Favorites

Newswise: 62d1e07f6d12f_Norrisstructure.jpg

Putting the brakes on "budding" viruses

Paramyxoviruses have the potential to trigger a devastating pandemic. This family of viruses includes measles, Nipah virus, mumps, Newcastle disease and canine distemper. An international team of collaborators has published the first-ever look at a...
17-Jul-2022 9:00 PM EDT Add to Favorites

Newswise: 62d6f0132e6ac_Lassavirus2022.png

LJI Scientists Discover Clue to Stopping Lassa Virus Infection

In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.
19-Jul-2022 2:10 PM EDT Add to Favorites

Newswise: 62ab7088e60cc_HMCRabies.jpg

Rethinking the Rabies Vaccine

Rabies virus kills a shocking 59,000 people each year, many of them children. In a new study, researchers from La Jolla Institute for Immunology and Institut Pasteur share a promising path to better vaccine design.
16-Jun-2022 2:50 PM EDT Add to Favorites

Newswise: 6296607eaff6d_50022918236e754b7287bc.jpg

LJI scientists publish first head-to-head comparison of four COVID-19 vaccines

"Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
31-May-2022 2:05 PM EDT Add to Favorites

Newswise: 6287d3331666c_cardiovasculardisease.jpg

Haywire T Cells Attack Protein In "Bad" Cholesterol

Detecting these T cells may lead to diagnostics to better detect heart disease—and disease severity.
20-May-2022 1:55 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: Erica_Saphire-300x300.png

Expert available to discuss Lassa virus and antibody therapies against the virus

26-Nov-2019 10:40 AM EST

Newswise: MatthiasvonHerrath.png

Dr. Matthias von Herrath named world’s leading type 1 diabetes expert

Dr. Matthias von Herrath, M.D., who founded the Type 1 Diabetes Center at La Jolla Institute for Immunology (LJI) has been identified as the world’s top expert in Type 1 Diabetes by Expertscape, an organization that provides tools to quickly and...
12-Dec-2018 11:05 AM EST

See All Experts

Our YouTube Videos

About

The La Jolla Institute for Immunology is dedicated to increasing knowledge and improving human health through studies of the immune system. Our essential purpose is to expand our understanding of how the immune system works and to discover the causes of immune system disorders. The knowledge gained through our biomedical research can, in turn lead to the prevention, treatment and cure of a wide range of human diseases.

Experts

Contacts

Gina Kirchweger
Chief Communications Officer
allergy immunology

gina@lji.org

858-752-6640

Jenna Hambrick
Digital Strategist

jhambrick@lji.org

858.752.6645

Madeline McCurry-Schmidt
Science Writer

madeline@lji.org

619-438-2382

Twitter

close
0.43344